AOD-9604 vs Semaglutide
Semaglutide is an FDA/EMA-approved GLP-1 agonist with robust clinical trial data. AOD-9604 is a research peptide with GRAS status but limited human efficacy data. They work through entirely different mechanisms.
Last updated: 2026-03-08
AOD-9604 and Semaglutide are both researched for their effects on body composition and fat metabolism, but they represent fundamentally different approaches — and vastly different levels of clinical evidence.
Semaglutide is a GLP-1 receptor agonist with extensive Phase III trial data, FDA and EMA approval, and millions of patients treated. AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) with GRAS (Generally Recognised As Safe) status but limited published human efficacy data.
This comparison examines their mechanisms, evidence, and practical considerations for researchers and clinicians.
**Important Note:** Semaglutide is a prescription medication. AOD-9604 is a research peptide not approved for human therapeutic use. This comparison is for educational purposes only.
Quick Comparison Table
| Category | AOD-9604 | Semaglutide |
|---|---|---|
| Drug Class | Modified GH fragment (aa 177-191) | GLP-1 receptor agonist |
| Mechanism | Direct lipolysis via fat cell β3-adrenergic pathway | Central appetite suppression + insulin sensitisation |
| Administration | Subcutaneous injection (daily) | Subcutaneous injection (weekly) |
| Regulatory Status | GRAS status (TGA Australia). Not approved as therapeutic | FDA/EMA approved for T2D and obesity |
| Human Trial Data | Limited Phase II data, mixed results | Extensive Phase III data (STEP trials, 10,000+ patients) |
| Weight Loss Efficacy | Modest (2-3 kg in limited trials) | Substantial (15-17% body weight in STEP trials) |
| GH Effects | No IGF-1 elevation, no GH-like effects | No GH pathway involvement |
| Cost | Lower (research peptide pricing) | Higher (pharmaceutical pricing) |
How They Work: Completely Different Pathways
AOD-9604
AOD-9604 Mechanism:
AOD-9604 is a modified fragment of human growth hormone consisting of amino acids 177-191 with an additional tyrosine at the N-terminus. It was designed to isolate the fat-metabolising properties of GH without its growth-promoting effects.
Key Mechanism: 1. AOD-9604 stimulates lipolysis (fat breakdown) in adipose tissue 2. Acts via β3-adrenergic receptor pathways on fat cells 3. Inhibits lipogenesis (new fat formation) 4. Does NOT bind to GH receptors — no IGF-1 elevation 5. Does NOT promote growth of muscle, bone, or organs
Selectivity: The fragment was engineered to separate GH's metabolic effects from its growth effects. In animal studies, AOD-9604 reduced body fat without affecting lean mass, IGF-1 levels, or insulin sensitivity — essentially a "fat-loss only" fragment.
Limitations: - The mechanism primarily targets stored fat metabolism - No appetite suppression — users must control caloric intake independently - The effect size in human trials has been modest compared to the animal data
Semaglutide
Semaglutide Mechanism:
Semaglutide is a synthetic GLP-1 (glucagon-like peptide-1) analogue with 94% homology to native human GLP-1, modified with a C-18 fatty acid chain that binds albumin, extending its half-life to ~7 days (enabling once-weekly dosing).
Key Mechanisms: 1. Central appetite suppression: Activates GLP-1 receptors in the hypothalamus and brainstem, reducing hunger and increasing satiety 2. Delayed gastric emptying: Slows stomach emptying, creating prolonged fullness after meals 3. Insulin sensitisation: Enhances glucose-dependent insulin secretion from pancreatic β-cells 4. Glucagon suppression: Reduces hepatic glucose output 5. Potential reward pathway modulation: May reduce food-related reward signalling
Why It Works So Well: Semaglutide addresses the biological drivers of obesity — it doesn't just burn fat; it reduces the drive to eat. This is why it produces 15-17% body weight loss vs 2-5% with most other interventions.
Comprehensive Effect: Unlike AOD-9604's isolated fat metabolism effect, semaglutide produces multi-system metabolic improvement: reduced cardiovascular risk (SELECT trial), improved insulin sensitivity, reduced inflammation, and liver fat reduction.
Clinical Trial Evidence
AOD-9604 Clinical Studies
Design: Review
) and non-peptidic (selective androgen receptor modulators, hypoxia-inducible factor stabilizers, siRNA, S-107 and ARM036/aladorian, etc. ) as well as inorganic (cobalt) nature are considered and discussed in terms of specific requirements originating from physicochemical properties, concentration levels, metabolism, and their amenability for chromatographic-mass spectrometric or alternative detection methods.
View study — PubMed 24906629Design: Review
Of these, only rimonabant has got as far as completing phase III clinical trials. This review will provide an overview of the most prominent drugs currently undergoing clinical development as potential anti-obesity therapies.
View study — PubMed 16625817Design: Review
Uk Metabolic is developing AOD-9604 for the potential treatment of obesity. By February 2002, phase IIa trials were underway.
View study — PubMed 15134286Design: Study
The stability of the peptides in urine was tested, and -20°C was found to be the appropriate storage temperature for sports drug testing. Finally, proof-of-concept was shown by analysing elimination study urine samples collected from individuals having administered GHRP-6, GHRP-2, or LHRH.
View study — PubMed 26578461Semaglutide Clinical Studies
Design: Meta-analysis
Participants: 2,258 participants
Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.
View study — PubMed 39719170Design: Meta-analysis
Participants: 2,372 participants
In this systematic review and meta-analysis, discontinuing GLP-1RA treatment led to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.
View study — PubMed 40186344Design: Meta-analysis
Participants: 246 participants
GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss.
View study — PubMed 38286487Design: Meta-analysis
Participants: 28 participants
Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.
View study — PubMed 38613667Benefits Comparison
AOD-9604 Unique Benefits
- No GH-related side effects (no IGF-1 elevation)
- No appetite changes — doesn't cause nausea
- GRAS safety status
- Lower cost than pharmaceutical GLP-1s
- May have joint health benefits (early data)
- No water retention or metabolic disruption
Shared Benefits
- Target fat loss / body composition improvement
- Subcutaneous administration
- Do not affect lean muscle mass directly
Semaglutide Unique Benefits
- 15-17% body weight loss (far superior efficacy)
- Cardiovascular risk reduction (SELECT trial)
- Kidney protection (FLOW trial)
- HbA1c improvement in T2D
- Once-weekly dosing convenience
- Pharmaceutical quality manufacturing
- Extensive long-term safety data
Research & Evidence
AOD-9604 Research
AOD-9604 has limited published human data — primarily one Phase II trial (n=300) showing modest efficacy (2-3 kg weight loss). The majority of compelling data is from preclinical (rodent) studies. Development as a weight loss drug was essentially abandoned after disappointing Phase II results.
Semaglutide Research
Semaglutide has the most extensive clinical trial programme of any obesity medication in history. The STEP programme enrolled >10,000 patients across multiple Phase III trials. The SELECT cardiovascular outcomes trial enrolled >17,000 patients over nearly 4 years. Post-marketing data includes millions of patients.
Head-to-Head Analysis
There are no head-to-head studies comparing AOD-9604 to semaglutide. Given the enormous difference in evidence quality and efficacy data, such a comparison would be difficult to justify ethically in a clinical trial setting. Semaglutide's 15% weight loss vs AOD-9604's 2-3% loss makes the efficacy gap clear from available data.
Protocol Comparison
AOD-9604 Protocol
AOD-9604 research protocols typically use 250-300 mcg per day via subcutaneous injection, often divided into 1-2 doses. Morning administration on an empty stomach is common. Research cycles of 8-12 weeks are typical. No official therapeutic protocol exists.
Semaglutide Protocol
Semaglutide for obesity (Wegovy): Start 0.25mg weekly for 4 weeks, titrate to 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg weekly over 16 weeks. This slow titration minimises GI side effects. Injected once weekly on the same day.
Combined Use
There is no research on combining AOD-9604 with semaglutide. Given that they work through entirely different mechanisms (direct lipolysis vs central appetite suppression), a theoretical case could be made for complementary effects. However, the GI side effects of semaglutide already limit caloric intake significantly, and adding AOD-9604's modest lipolytic effect may not provide meaningful additional benefit. This combination has not been studied and cannot be recommended.
Safety Profiles
AOD-9604 Safety
AOD-9604 has a favourable safety profile based on available data. The GRAS designation from TGA Australia confirms no significant safety concerns. Key safety advantages include: no IGF-1 elevation, no effect on glucose or insulin, no water retention, no appetite changes, and minimal injection site reactions. The main safety concern is the limited long-term human data — we simply don't know the effects of chronic use because it hasn't been adequately studied.
Semaglutide Safety
Semaglutide has extensive safety data from clinical trials and post-marketing surveillance. Common side effects include nausea (44%), diarrhoea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%) — mostly GI and typically improving with continued use. Serious but rare risks include pancreatitis, gallbladder disease, and thyroid C-cell tumour concern (rodent signal). The SELECT trial provided reassurance about cardiovascular safety. The risk-benefit assessment has been judged favourable by both FDA and EMA.
The Verdict: When to Choose Which?
Choose AOD-9604 When:
- When GI side effects of GLP-1s are intolerable
- When appetite is well-controlled and direct lipolysis is the goal
- When budget is limited
- When looking for a peptide with minimal systemic effects
Choose Semaglutide When:
- When maximum evidence-based weight loss is the priority
- When cardiovascular risk reduction is important
- When type 2 diabetes co-management is needed
- When you want pharmaceutical-grade quality assurance
- When once-weekly convenience is valued
Consider Combining When:
- No evidence supports combining these peptides
- Different mechanisms theoretically allow combination, but this is unstudied
- Consult a healthcare professional if considering any combination approach
Frequently Asked Questions
Conclusion
AOD-9604 and semaglutide represent opposite ends of the evidence spectrum in fat loss research. Semaglutide is one of the most thoroughly validated medications in history, with proven efficacy, cardiovascular benefits, and regulatory approval worldwide. AOD-9604 is a research peptide with an interesting mechanism but disappointing clinical trial results and limited human data.
For evidence-based fat loss, semaglutide (or tirzepatide) remains the clear choice for those who can access and tolerate it. AOD-9604 may have a niche role for researchers interested in its unique mechanism or those who cannot tolerate GLP-1 agonists, but expectations should be calibrated to the modest clinical data.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither AOD-9604 nor Semaglutide is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.